References
Beck L,
Karaplis AC,
Amizuka N et al.
(1998)
Targeted inactivation of Npt2 in mice leads to severe renal phosphate wasting, hypercalciuria, and skeletal abnormalities.
Proceedings of the National Academy of Sciences of the USA
95(9):
5372–5377.
Bergwitz C,
Roslin NM,
Tieder M et al.
(2006)
SLC34A3 mutations in patients with hereditary hypophosphatemic rickets with hypercalciuria predict a key role for the sodium‐phosphate cotransporter NaPi‐IIc in maintaining phosphate homeostasis.
American Journal of Human Genetics
78(2):
179–192.
Berndt T,
Craig TA,
Bowe AE et al.
(2003)
Secreted frizzled‐related protein 4 is a potent tumor‐derived phosphaturic agent.
Journal of Clinical Investigation
112(5):
785–794.
Bianchine JW,
Stambler AA and
Harrison HE
(1971)
Familial hypophosphatemic rickets showing autosomal dominant inheritance.
Birth Defects Original Article Series
7(6):
287–295.
Bowe AE,
Finnegan R,
Jan de Beur SM et al.
(2001)
FGF‐23 inhibits renal tubular phosphate transport and is a PHEX substrate.
Biochemical and Biophysical Research Communications
284(4):
977–981.
David L,
Pesso JL,
Cochat P,
Plauchu H and
Francois R
(1987)
Rachitisme hypophosphatémique autosomique type Scriver: Une observation familiale.
Pédiatrie
42:
563–568.
DiMeglio LA,
White KE and
Econs MJ
(2000)
Disorders of phosphate metabolism.
Endocrinology and Metabolism Clinics of North America
29(3):
591–609.
Econs MJ and
McEnery PT
(1997)
Autosomal dominant hypophosphatemic rickets/osteomalacia: clinical characterization of a novel renal phosphate wasting disorder.
The Journal of Clinical Endocrinology and Metabolism
8:
674–681.
Feng JQ,
Ward LM,
Liu S et al.
(2006)
Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism.
Nature Genetics
38(11):
1310–1315.
Forster IC,
Hernando N,
Biber J and
Murer H
(2006)
Proximal tubular handling of phosphate: a molecular perspective.
Kidney International
70(9):
1548–1559.
Hardy DC,
Murphy WA,
Siegel BA,
Reid IR and
Whyte MP
(1989)
X‐linked hypophosphatemia: prevalence of skeletal radiographic and scintigraphic features.
Radiology
171:
403–414.
HYP consortium
(1995)
A gene (PEX) with homologies to endopeptidases is mutated in patients with X‐linked hypophosphatemic rickets.
Nature Genetics
11:
130–136.
Ichikawa S,
Sorenson AH,
Imel EA et al.
(2006)
Intronic deletions in the SLC34A3 gene cause hereditary hypophosphatemic rickets with hypercalciuria.
The Journal of Clinical Endocrinology and Metabolism
91(10):
4022–4027.
Jain A,
Fedarko NS,
Collins MT et al.
(2004)
Serum levels of matrix extracellular phosphoglycoprotein (MEPE) in normal humans correlate with serum phosphorus, parathyroid hormone and bone mineral density.
The Journal of Clinical Endocrinology and Metabolism
89(8):
4158–4161.
Ling Y,
Rios HF,
Myers ER et al.
(2005)
DMP1 depletion decreases bone mineralization in vivo: an FTIR imaging analysis.
Journal of Bone and Mineral Research
20(12):
2169–2177.
Lipman ML,
Panda D,
Bennett HPJ et al.
(1998)
Cloning of human PEX cDNA. Expresssion, subcelular localization nad endopeptidase activity.
Journal of Biological Chemistry
273:
13729.
Liu S,
Rowe PS,
Vierthaler L,
Zhou J and
Quarles LD
(2007)
Phosphorylated acidic serine‐aspartate‐rich MEPE‐associated motif peptide from matrix extracellular phosphoglycoprotein inhibits phosphate regulating gene with homologies to endopeptidases on the X‐chromosome enzyme activity.
Journal of Endocrinology
192(1):
261–267.
Lorenz‐Depiereux B,
Bastepe M,
Benet‐Pages A et al.
(2006a)
DMP1 mutations in autosomal recessive hypophosphatemia implicate a bone matrix protein in the regulation of phosphate homeostasis.
Nature Genetics
38(11):
1248–1250.
Lorenz‐Depiereux B,
Benet Pages A,
Eckstein G et al.
(2006b)
Hereditary hypophosphatemic rickets with hypercalciuria is caused by mutations in the sodium‐phosphate cotransporter SLC34A3.
American Journal of Human Genetics
78(2):
193–201.
Machler M,
Frey D,
Gal A et al.
(1986)
X‐linked dominant hypophosphatemia is closely linked to DNA markers DXS41 and DXS43 at XCp22.
Human Genetics
73:
271–275.
Madjdpour C,
Bacic D,
Kassiling B,
Murer H and
Biber J
(2004)
Segment‐specific expression of sodium‐phosphate cotransporters NaPi‐IIa and ‐IIc and interacting proteins in mouse renal proximal tubules.
Pflugers Archive
448(4):
402–410.
Meyer RA Jr,
Meyer MH and
Gray RW
(1989)
Parabiosis suggests a humoral factor is involved in X‐linked hypophosphatemia in mice.
Journal of Bone and Mineral Research
4(4):
493–500.
Murer H,
Hernando N,
Forster I and
Biber J
(2001)
Molecular aspects in the regulation in inorganic phosphate reabsorption: the type IIa sodium/inorganic phosphate cotransporter as the key player.
Current Opinion in Nephrology and Hypertension
10:
555–561.
Nesbitt T,
Coffman TM,
Griffiths R and
Drezner MK
(1992)
Crosstransplantation of kidneys in normal and Hyp mice. Evidence that the Hyp mouse phenotype is unrelated to an intrinsic renal defect.
Journal of Clinical Investigation
89(5):
1453–1459.
Polisson RP,
Martinez S,
Khoury M et al.
(1985)
Calcifications of entheses associated with X‐linked hypophosphatemic osteomalacia.
The New England Journal of Medicine
313:
1–6.
Prié D,
Huart V,
Bakouh N et al.
(2002)
Nephrolithiasis and osteoporosis associated with hypophosphatemia caused by mutations in the type 2a sodium‐phosphate cotransporter.
The New England Journal of Medicine
347(13):
983–991.
Quarles LD
(2003)
Evidence for a bone‐kidney axis regulating phosphate homeostasis.
Journal of Clinical Investigation
112(5):
642–646.
Reid IR,
Hardy DC,
Murphy WA et al.
(1989)
X‐linked hypophosphatemia: a clinical, biochemical and histopatologic assessment of morbidity in adults.
Medicine
68:
336–352.
Reid IR,
Murphy WA,
Hardy DC et al.
(1991)
X‐linked hypophosphatemia: skeletal mass in adults assessed by histomorphometry, computed tomography and absorptiometry.
American Journal of Medicine
90:
63–69.
Rowe PS,
Kumagai Y,
Gutierrez G et al.
(2004)
MEPE has the properties of an osteoblastic phosphatonin and minhibin.
Bone
34(2):
303–319.
Rowe PSN,
Oudet CL,
Francis F et al.
(1997)
PEX mutations in families with X‐linked hypophosphatemic rickets.
Human Molecular Genetics
6:
539–549.
Ruchon AF,
Marcinkiewwicz M,
Siegfried G et al.
(1998)
Pex mRNA is localized in developing mouse osteoblasts and odontoblasts.
The Journal of Histochemistry and Cytochemistry
46:
459–468.
Saito H,
Kusano K,
Kinosaki M et al.
(2003)
Human fibroblast growth factor‐23 mutants suppress Na+‐dependent phosphate cotransport activity and 1alpha,25‐dihydroxyvitamin D3 production.
Journalc of Biological Chemistry
278(4):
2206–2211.
Scriver CR,
MacDonald W,
Reade T,
Glorieux FH and
Nogrady B
(1977)
Hypophosphatemic nonrachitic bone disease: an entity distinct from X‐linked hypophophatemia in the renal defect, bone involvement, and inheritance.
American Journal of Medicinal Genetics
1:
101–117.
Shimada T,
Hasegawa H,
Yamazaki Y et al.
(2004a)
FGF‐23 is a potent regulator of vitamin D metabolism and phosphate homeostasis.
Journal of Bone and Mineral Research
19(3):
429–435.
Shimada T,
Kakitani M,
Yamazaki Y et al.
(2004b)
Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism.
Journal of Clinical Investigation
113(4):
561–568.
Shimada T,
Mizutani S,
Muto T et al.
(2001)
Cloning and characterization of FGF23 as a causative factor of tumor‐induced osteomalacia.
Proceedings of the National Academy of Sciences of the USA
98(11):
6500–6505.
Tieder M,
Modai D,
Samuel R et al.
(1985)
Hereditary hypophosphatemic rickets with hypercalciuria.
The New England Journal of Medicine
312:
611–616.
Toyosawa S,
Shintani S,
Fujiwara T et al.
(2001)
Dentin matrix protein 1 is predominantly expressed in chicken and rat osteocytes but not in osteoblasts.
Journal of Bone and Mineral Research
16(11):
2017–2026.
Vera CI,
Curo JK,
Naso WB et al.
(1997)
Paraplegia due to ossification of Ligamenta flava in X‐linked hypophopsphatemia.
Spine
22:
710.
White KE,
Evans WE,
O'Riordan JL et al.
(2000)
Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. The ADHR Consortium.
Nature Genetics
26(3):
345–348.
White KE,
Jonsson KB,
Carn G et al.
(2001)
The autosomal dominant hypophosphatemic rickets (ADHR) gene is a secreted polypeptide overexpressed by tumors that cause phosphate wasting.
The Journal of Clinical Endocrinology and Metabolism
86(2):
497–500.
Winters RW,
Graham JB,
Williams TF,
Falls MC and
Burnett CHH
(1958)
A genetic study of familial hypophosphatemia and vitamin D‐resistant rickets with review of the literature.
Medicine
37:
97–142.
Yamashita T,
Konishi M,
Miyake A,
Inui K and
Itoh N
(2002)
Fibroblast growth factor (FGF)‐23 inhibits renal phosphate reabsorption by activation of the mitogen‐activated protein kinase pathway.
Journal of Biological Chemistry
277(31):
28265–28270.
Futher Reading
Fukumoto S
(2008)
Physiological regulation and disorders of phosphate metabolism – pivotal role of fibroblast growth factor 23.
Internal Medicine
47(5):
337–343.
Imel EA,
Hui SL and
Econs MJ
(2007)
FGF23 concentrations vary with disease status in autosomal dominant hypophosphatemic rickets.
Journal of Bone and Mineral Research
22(4):
520–526.
Liu S,
Zhou J,
Tang W et al.
(2006)
Pathogenic role of Fgf23 in Hyp mice.
American Journal of Physiology. Endocrinology and Metabolism
291(1):
E38–E49.
Qin C,
D'Souza R and
Feng JQ
(2007)
Dentin matrix protein 1 (DMP1): new and important roles for biomineralization and phosphate homeostasis.
Journal of Dental Research
86(12):
1134–1141.
Yamamoto T,
Michigami T and
Aranami F
(2007)
Hereditary hypophosphatemic rickets with hypercalciuria: a study for the phosphate transporter gene type IIc and osteoblastic function.
Journal of Bone and Mineral Metabolism
25(6):
407–413.